Approaches to Individualized Treatment for Chronic Lymphocytic Leukemia: Expert Guidance on Sequencing Therapy, Novel Agents, and their Combinations
The goal of this program is to improve the knowledge and competence of clinicians to implement best practices in the treatment of CLL.
Provided by NCCN in partnership with Clinical Care Options, LLC
This program is intended for physicians, nurses, pharmacists, and other health care providers who treat and manage patients with chronic lymphocytic leukemia.
Upon completion of this activity, participants should be able to:
- Consider the efficacy and safety profile of the therapeutic agent along with patient characteristics and molecular features of CLL to individualize therapeutic strategies for newly diagnosed CLL.
- Choose optimal treatment for relapsed/refractory CLL based on the available clinical data, guidelines, and expert recommendations.
- Plan treatment strategies that sequence targeted agents to optimize patient outcomes and quality of life.
- Evaluate the efficacy, toxicity profile, and other practical management considerations associated with novel approved and investigational agents and combination regimens in CLL.
- Manage adverse events associated with treatment approaches for CLL to ensure treatment compliance to improve clinical outcomes and quality of life.
Jeremy S. Abramson, MD, MMSc
Massachusetts General Hospital Cancer Center
William G. Wierda, MD, PhD
The University of Texas MD Anderson Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.
The faculty, NCCN staff, and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
The faculty listed below discloses the following relevant financial relationships:
Jeremy S. Abramson, MD, MMSc
AbbVie, Inc.: Consulting Fee
Bayer HealthCare: Consulting Fee
Celgene Corporation: Consulting Fee
EMD Serono: Consulting Fee
Genentech, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
Karyopharm Therapeutics: Consulting Fee
Kite Pharma: Consulting Fee
Roche Laboratories, Inc.: Consulting Fee
William G. Wierda, MD, PhD
AbbVie, Inc. Grant/Research Support
Acerta Pharma: Grant/Research Support
Cyclacel Pharmaceuticals, Inc.: Grant/Research Support
Genentech, Inc. Grant/Research Support
Genzyme Corporation: Consulting Fee
Gilead Sciences, Inc.: Grant/Research Support
GlaxoSmithKline/Novartis Pharmaceuticals Corporation: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support
Juno Therapeutics, Inc.: Grant/Research Support
Karyopharm Therapeutics: Grant/Research Support
Kite Pharma: Grant/Research Support
Loxo Oncology, Inc.: Grant/Research Support
miRagen Therapeutics, Inc.: Grant/Research Support
Oncternal Therapeutics, Inc.: Grant/Research Support
Pharmacyclics: Grant/Research Support
Sunesis Pharmaceuticals, Inc.: Grant/Research Support
Xencor, Inc.: Grant/Research Support
The activity planning staff listed below discloses no relevant financial relationships:
CCO: Bing-E Xu, PhD; Tiffany Hensley-McBain, PhD; Timothy Quill, PhD; Kevin Obholz, PhD
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Rashmi Kumar, PhD; Kathy Ann Smith, CHCP
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Hema Sundar, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-9999-19-072-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation